Michael H. Davidson to Schizophrenia
This is a "connection" page, showing publications Michael H. Davidson has written about Schizophrenia.
Connection Strength
9.496
-
The brief negative symptom scale (BNSS): Sensitivity to treatment effects. Schizophr Res. 2018 07; 197:269-273.
Score: 0.488
-
Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia. Am J Psychiatry. 2017 12 01; 174(12):1195-1202.
Score: 0.475
-
A population-based longitudinal study of suicide risk in male schizophrenia patients: Proximity to hospital discharge and the moderating effect of premorbid IQ. Schizophr Res. 2015 Dec; 169(1-3):159-164.
Score: 0.420
-
Bl-1020, a new ?-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. J Clin Psychiatry. 2012 Sep; 73(9):e1168-74.
Score: 0.338
-
CNS infection in childhood does not confer risk for later schizophrenia: a case-control study. Schizophr Res. 2010 Dec; 124(1-3):231-5.
Score: 0.295
-
Refractive errors and schizophrenia. Schizophr Res. 2009 Feb; 107(2-3):238-41.
Score: 0.260
-
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007 Jul; 93(1-3):117-30.
Score: 0.233
-
Premorbid functioning and treatment response in recent-onset schizophrenia. Br J Psychiatry. 2006 Jul; 189:31-5.
Score: 0.220
-
Premorbid intra-individual variability in intellectual performance and risk for schizophrenia: a population-based study. Schizophr Res. 2006 Jul; 85(1-3):49-57.
Score: 0.217
-
Premorbid intellectual functioning and risk of schizophrenia and spectrum disorders. J Clin Exp Neuropsychol. 2006 Feb; 28(2):193-207.
Score: 0.214
-
Elaboration on premorbid intellectual performance in schizophrenia: premorbid intellectual decline and risk for schizophrenia. Arch Gen Psychiatry. 2005 Dec; 62(12):1297-304.
Score: 0.212
-
Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry. 2005 Oct; 162(10):1888-95.
Score: 0.209
-
Body mass index and future schizophrenia in Israeli male adolescents. J Clin Psychiatry. 2004 Nov; 65(11):1546-9.
Score: 0.196
-
Higher rates of cigarette smoking in male adolescents before the onset of schizophrenia: a historical-prospective cohort study. Am J Psychiatry. 2004 Jul; 161(7):1219-23.
Score: 0.192
-
A population-based cohort study of premorbid intellectual, language, and behavioral functioning in patients with schizophrenia, schizoaffective disorder, and nonpsychotic bipolar disorder. Am J Psychiatry. 2002 Dec; 159(12):2027-35.
Score: 0.172
-
Risk of cardiovascular disease and sudden death in schizophrenia. J Clin Psychiatry. 2002; 63 Suppl 9:5-11.
Score: 0.161
-
Association between nonpsychotic psychiatric diagnoses in adolescent males and subsequent onset of schizophrenia. Arch Gen Psychiatry. 2001 Oct; 58(10):959-64.
Score: 0.159
-
Adjunctive Aspirin vs Placebo in Patients With Schizophrenia: Results of Two Randomized Controlled Trials. Schizophr Bull. 2021 07 08; 47(4):1077-1087.
Score: 0.156
-
Risperidone versus haloperidol in long-term hospitalized chronic patients in a double blind randomized trial: a post hoc analysis. Schizophr Res. 2001 May 30; 50(1-2):89-93.
Score: 0.155
-
Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial. J Clin Psychiatry. 2001 May; 62(5):343-6.
Score: 0.154
-
A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group. Int J Geriatr Psychiatry. 2000 Jun; 15(6):506-14.
Score: 0.145
-
Effect of Adjunctive Estradiol on Schizophrenia Among Women of Childbearing Age: A Randomized Clinical Trial. JAMA Psychiatry. 2019 10 01; 76(10):1009-1017.
Score: 0.138
-
Personal and social adjustment effects of roluperidone in patients with schizophrenia and negative symptoms: Results from an exploratory outcome of a randomized placebo-controlled trial. Schizophr Res. 2019 09; 211:103-104.
Score: 0.136
-
The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial. Schizophr Res. 2019 04; 206:325-332.
Score: 0.130
-
Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms: Results From a Randomized Controlled Trial. J Clin Psychiatry. 2018 May/Jun; 79(3).
Score: 0.125
-
The association between adaptive and cognitive deficits in geriatric chronic schizophrenic patients. Schizophr Res. 1997 Oct 30; 27(2-3):211-8.
Score: 0.121
-
Cognitive impairment in geriatric chronic schizophrenic patients: a cross-national study in New York and London. Int J Geriatr Psychiatry. 1997 Oct; 12(10):1001-7.
Score: 0.120
-
Apolipoprotein E4 in schizophrenia: a study of one hundred sixteen cases with concomitant neuropathological examination. Biol Psychiatry. 1997 Aug 15; 42(4):296-8.
Score: 0.119
-
Limitations of controlled augmentation trials in schizophrenia. Biol Psychiatry. 1997 Jul 15; 42(2):138-43.
Score: 0.118
-
Cognitive impairment and negative symptoms in geriatric chronic schizophrenic patients: a follow-up study. Schizophr Res. 1996 Dec 15; 22(3):223-31.
Score: 0.114
-
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry. 2017 Mar 01; 174(3):216-229.
Score: 0.114
-
Cognitive functioning in late-life schizophrenia: a comparison of elderly schizophrenic patients and patients with Alzheimer's disease. Am J Psychiatry. 1996 Oct; 153(10):1274-9.
Score: 0.112
-
Developmental Trajectories of Impaired Community Functioning in Schizophrenia. JAMA Psychiatry. 2016 Jan; 73(1):48-55.
Score: 0.106
-
The cost of cognitive impairment in schizophrenia. Schizophr Res. 1995 Sep; 17(1):1-3.
Score: 0.104
-
Cognitive functioning in chronically hospitalized schizophrenic patients: age-related changes and age disorientation as a predictor of impairment. Schizophr Res. 1995 Sep; 17(1):15-24.
Score: 0.104
-
The puzzle of processing speed, memory, and executive function impairments in schizophrenia: fitting the pieces together. Biol Psychiatry. 2015 Dec 01; 78(11):786-93.
Score: 0.100
-
Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. Am J Psychiatry. 1995 Feb; 152(2):197-207.
Score: 0.100
-
Memory functions in geriatric chronic schizophrenic patients: a neuropsychological study. J Neuropsychiatry Clin Neurosci. 1995; 7(2):207-12.
Score: 0.099
-
Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc Natl Acad Sci U S A. 1993 Oct 01; 90(19):8942-6.
Score: 0.091
-
Predictors of response to neuroleptic treatment in schizophrenia. Psychiatr Clin North Am. 1993 Jun; 16(2):313-38.
Score: 0.089
-
Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull. 2013 Nov; 39(6):1230-41.
Score: 0.089
-
Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study. Schizophr Res. 2013 Jun; 147(1):132-139.
Score: 0.088
-
Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry Res. 1993 Feb; 46(2):151-63.
Score: 0.087
-
Leukotomy and aging in chronic schizophrenia: a followup study 40 years after psychosurgery. Schizophr Bull. 1993; 19(4):723-32.
Score: 0.086
-
Family history of schizophrenia and bipolar disorder as risk factors for autism. Arch Gen Psychiatry. 2012 Nov; 69(11):1099-1103.
Score: 0.085
-
Dedifferentiation and substitute strategy: deconstructing the processing-speed impairment in schizophrenia. Schizophr Res. 2012 Dec; 142(1-3):129-36.
Score: 0.085
-
A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry. 2012 Jun; 73(6):e728-34.
Score: 0.083
-
Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991 Nov; 148(11):1474-86.
Score: 0.080
-
Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations. Arch Gen Psychiatry. 1991 Oct; 48(10):910-3.
Score: 0.079
-
Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation. Arch Gen Psychiatry. 1991 Jan; 48(1):73-6.
Score: 0.075
-
Strong synaptic transmission impact by copy number variations in schizophrenia. Proc Natl Acad Sci U S A. 2010 Jun 08; 107(23):10584-9.
Score: 0.072
-
Increments in plasma homovanillic acid concentrations after neuroleptic discontinuation are associated with worsening of schizophrenic symptoms. Prog Neuropsychopharmacol Biol Psychiatry. 1990; 14(6):879-84.
Score: 0.070
-
Measurement of plasma homovanillic acid concentrations in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 1990; 14(3):271-87.
Score: 0.070
-
Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST). J Clin Psychiatry. 2010 Jan; 71(1):58-65.
Score: 0.069
-
Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res. 2009 Dec; 115(2-3):97-103.
Score: 0.069
-
Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry. 2009 Jun; 166(6):675-82.
Score: 0.067
-
What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull. 2010 May; 36(3):504-9.
Score: 0.064
-
A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls. Arch Gen Psychiatry. 1988 Jun; 45(6):561-3.
Score: 0.063
-
A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res. 2006 Jul; 85(1-3):254-65.
Score: 0.055
-
Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder. Int J Geriatr Psychiatry. 2004 Sep; 19(9):898-905.
Score: 0.049
-
Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004; 65 Suppl 7:4-18; quiz 19-20.
Score: 0.046
-
Convergence of cognitive and adaptive decline in late-life schizophrenia. Schizophr Res. 1999 Jan 04; 35(1):77-84.
Score: 0.033
-
Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiatry. 1998 Aug; 155(8):1080-6.
Score: 0.032
-
Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. Arch Gen Psychiatry. 1998 Mar; 55(3):205-11.
Score: 0.031
-
Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia. Arch Gen Psychiatry. 1997 Jun; 54(6):559-66.
Score: 0.029
-
Characteristics of elderly psychiatric patients retained in a state hospital during downsizing: a prospective study with replication. Int J Geriatr Psychiatry. 1997 Apr; 12(4):474-80.
Score: 0.029
-
Age-related differences in formal thought disorder in chronically hospitalized schizophrenic patients: a cross-sectional study across nine decades. Am J Psychiatry. 1997 Feb; 154(2):205-10.
Score: 0.029
-
Social-Adaptive Functioning Evaluation (SAFE): a rating scale for geriatric psychiatric patients. Schizophr Bull. 1997; 23(1):131-45.
Score: 0.029
-
Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale. Biol Psychiatry. 1996 Oct 15; 40(8):755-60.
Score: 0.028
-
Clinical characteristics of Kraepelinian schizophrenia: replication and extension of previous findings. Am J Psychiatry. 1996 Jun; 153(6):806-11.
Score: 0.027
-
Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex. Biol Psychiatry. 1996 Jan 15; 39(2):82-91.
Score: 0.027
-
Cognitive function and biological correlates of cognitive performance in schizotypal personality disorder. Psychiatry Res. 1995 Nov 29; 59(1-2):127-36.
Score: 0.026
-
A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. Schizophr Res. 1995 Sep; 17(1):25-33.
Score: 0.026
-
Validity and utility of the ADAS-L for measurement of cognitive and functional impairment in geriatric schizophrenic inpatients. J Neuropsychiatry Clin Neurosci. 1995; 7(1):76-81.
Score: 0.025
-
Clozapine treatment and its effect on neuroendocrine responses induced by the serotonin agonist, m-chlorophenylpiperazine. Biol Psychiatry. 1994 Jun 15; 35(12):909-12.
Score: 0.024
-
Cortical cholinergic markers in schizophrenia. Schizophr Res. 1994 May; 12(2):137-44.
Score: 0.024
-
Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function. Schizophr Res. 1994 Feb; 11(3):217-24.
Score: 0.023
-
Alzheimer's-disease-related protein in geriatric schizophrenic patients with cognitive impairment. Am J Psychiatry. 1993 Nov; 150(11):1726-7.
Score: 0.023
-
Serotonin function and treatment response to clozapine in schizophrenic patients. Am J Psychiatry. 1993 Sep; 150(9):1337-42.
Score: 0.023
-
Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment. Arch Gen Psychiatry. 1993 Aug; 50(8):599-605.
Score: 0.023
-
Schizophrenia-related and affective personality disorder traits in relatives of probands with schizophrenia and personality disorders. Am J Psychiatry. 1993 Mar; 150(3):435-42.
Score: 0.022
-
Severe cognitive impairment in elderly schizophrenic patients: a clinicopathological study. Biol Psychiatry. 1993 Feb 15; 33(4):255-60.
Score: 0.022
-
Haloperidol and clozapine treatment and their effect on M-chlorophenylpiperazine-mediated responses in schizophrenia: implications for the mechanism of action of clozapine. Psychopharmacology (Berl). 1993; 112(1 Suppl):S90-4.
Score: 0.022
-
Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: negative symptoms. Psychiatry Res. 1992 Nov; 44(2):153-65.
Score: 0.021
-
Assessment of dementia in elderly schizophrenics with structured rating scales. Schizophr Res. 1992 Apr; 7(1):85-90.
Score: 0.021
-
Effect of concurrent distraction on communication failures in schizophrenic patients. II. Medication status correlations. Schizophr Res. 1991 Sep; 5(2):153-9.
Score: 0.020
-
Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients. Psychiatry Res. 1991 Sep; 38(3):285-92.
Score: 0.020
-
Time course and clinical predictors of treatment response in schizophrenia. Schizophr Res. 1991 Sep; 5(2):161-6.
Score: 0.020
-
Continuous performance tests in schizophrenic patients: stimulus and medication effects on performance. Psychiatry Res. 1991 Apr; 37(1):47-56.
Score: 0.019
-
Impaired reading comprehension and mathematical abilities in male adolescents with average or above general intellectual abilities are associated with comorbid and future psychopathology. J Nerv Ment Dis. 2007 Nov; 195(11):883-90.
Score: 0.015
-
Paternal age and intelligence: implications for age-related genomic changes in male germ cells. Psychiatr Genet. 2005 Jun; 15(2):117-25.
Score: 0.013
-
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry. 2005 May; 162(5):947-53.
Score: 0.013
-
Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. J Clin Psychiatry. 2002; 63 Suppl 9:25-9.
Score: 0.010
-
Galanin-like immunoreactivity is increased in the postmortem cerebral cortex from patients with Alzheimer's disease. J Neurochem. 1994 Apr; 62(4):1516-23.
Score: 0.006